Learn From the Experts About Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond
 |
Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents |
|
Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents |
|
Emerging Therapies for Multiple Myeloma |
|
Emerging Therapies for Hodgkin Lymphoma |
|
Risk-Adapted Treatment of Acute Myelogenous Leukemia |
|
Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms |
|
Learn From the Experts About Clinical Advances and Case Studies in Immune Checkpoint Inhibitors in Oncology
|
Overview of the Immune System and Immune Checkpoint Targets and their MOAs |
|
Treatment-Related Issues |
|
Management of Immune-Related Adverse Events |
|
Renal Cell Carcinoma |
|
Non–Small Cell Lung Cancer |
|
Melanoma |
|
Mismatch Repair Deficiency/Microsatellite Instability-High Cancers |
|
Head and Neck Cancer |
|
Urothelial Carcinoma |
|
